Zobrazeno 1 - 10 of 53 pro vyhledávání: '"Valentin García-Gutiérrez"'
1
Akademický článek
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Autor: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro, Jorge E. Cortes
Publikováno v: Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-15 (2022)
Abstract Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib,
Externí odkaz: https://doaj.org/article/d58ac9e3f8574a0c98a83bd01d059e40
Zobrazit plný text záznamu
3
Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase
Autor: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro, Jorge E. Cortes
Publikováno v: Kompass Onkologie. 10:2-14
Tyrosinkinase-Inhibitoren (TKIs) haben die langfristigen Behandlungsergebnisse für Patienten mit chronischer myeloischer Leukämie (CML) erheblich verbessert. Nach Imatinib (einem TKI der ersten Generation) wurden TKIs der zweiten und dritten Genera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22cfdbc1631c7de77beabe38b052d0db
https://doi.org/10.1159/000529704
Zobrazit plný text záznamu
4
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
Autor: Valentin García-Gutiérrez, Juan Carlos Hernandez-Boluda
Publikováno v: Expert Review of Hematology. 15:477-484
To date, five tyrosine kinase inhibitors (TKIs) are available for treating chronic myeloid leukemia (CML) patients in clinical practice. Despite this, a significant proportion of patients will ultimately develop failure to approved TKIs due to intole
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3026c83984bb8c2239d4b67c2764609
https://doi.org/10.1080/17474086.2022.2080049
Zobrazit plný text záznamu
5
Akademický článek
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Autor: Valentin Garcia-Gutierrez, Fei Huang, Ajibade Ashaye, Mehul Dalal, Victor Laliman-Khara, Massimo Breccia, Megan Rutherford, Hoora Moradian, Petros Patos, Elias Joseph Jabbour
Publikováno v: Frontiers in Oncology, Vol 14 (2024)
BackgroundPonatinib and asciminib are approved for third-line therapy in chronic-phase chronic myeloid leukemia (CP-CML) and are the only drugs approved for patients with the T315I mutation in the United States. In Europe, only ponatinib is approved
Externí odkaz: https://doaj.org/article/ed2b0ee3852f4e13af5b8674b7755ddf
Zobrazit plný text záznamu
6
Akademický článek
Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib
Autor: Mario Manzanares, Fernando Ramos-Martín, Sara Rodríguez-Mora, Guiomar Casado-Fernández, Clara Sánchez-Menéndez, Alicia Simón-Rueda, Elena Mateos, Miguel Cervero, Adam M. Spivak, Vicente Planelles, Montserrat Torres, Valentín García-Gutiérrez, Mayte Coiras
Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)
HIV-1 infection cannot be cured due to long-lived viral reservoirs formed by latently infected CD4+ T cells. “Shock and Kill” strategy has been considered to eliminate the viral reservoir and achieve a functional cure but the stimulation of cytot
Externí odkaz: https://doaj.org/article/9854eb1f037746858c873d3668929237
Zobrazit plný text záznamu
8
Akademický článek
Different polarization and functionality of CD4+ T helper subsets in people with post-COVID condition
Autor: Clara Sánchez-Menéndez, Olivia de la Calle-Jiménez, Elena Mateos, Lorena Vigón, Daniel Fuertes, María Aranzazu Murciano Antón, Esther San José, Valentín García-Gutiérrez, Miguel Cervero, Montserrat Torres, Mayte Coiras
Publikováno v: Frontiers in Immunology, Vol 15 (2024)
IntroductionAfter mild COVID-19 that does not require hospitalization, some individuals develop persistent symptoms that may worsen over time, producing a multisystemic condition termed Post-COVID condition (PCC). Among other disorders, PCC is charac
Externí odkaz: https://doaj.org/article/108279de07d54303b95dafdd14a8805d
Zobrazit plný text záznamu
9
Akademický článek
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
Autor: Valentín García-Gutiérrez, María Teresa Gómez-Casares, Blanca Xicoy, Felipe Casado-Montero, Guillermo Orti, Pilar Giraldo, Juan Carlos Hernández-Boluda
Publikováno v: Frontiers in Oncology, Vol 14 (2024)
Chronic myeloid leukemia (CML), characterized by the presence of the BCR::ABL1 fusion gene, has undergone a transformative shift with the introduction of tyrosine kinase inhibitors (TKIs). The current availability of six different TKIs (imatinib, das
Externí odkaz: https://doaj.org/article/171f72ea8b64423490f5a5a108df9b36
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje